Swiss drugmaker Novartis said fourth-quarter core operating income rose 11 percent in constant currencies, as sales of its Entresto heart failure medicine accelerated along with revenue from its psoriasis-and-arthritis blockbuster Cosentyx. ...... read full story
Photo: Novartis in the Suurstoffi, Red Cross.